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Dansyl-labeled tetrapeptide Gly-His-Arg-Pro which mimics the central fibrin polymerization site was used to investigate its binding to a number 
of fibrinogen fragments containing different numbers of domains. The tetrapeptide was found to bind to fragments D,(95 kDa), D&32 kDa) and 
D,(63 kDa) but not to the TSD(28 kDa) fragment. The D, fragment differs from the TSD by the presence of /I and/K domains. Therefore these 
domains, which are formed by the C-terminal part of the j3 chain, possess a polymerization site complementary to the Gly-His-Arg containing 
counterpart. 
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1. INTRODUCTION 
Polymerization of fibrin occurs due to the interaction 
between complementary polymerization sites. The fi- 
brinogen molecule has two sets of these sites; one situ- 
ated in the central part, another one in each terminal 
part of the molecule [I]. The cleavage of fibrinopeptides 
A and B (FPA and FPB) by thrombin from the N- 
terminal parts of the fibrinogen Aa and Bj? polypeptide 
chains leads to an exposure of the central set of the 
polymerization sites and spontaneous fibrin polymeri- 
zation due to the interaction of the latter with the com- 
plementary sites located in the terminal regions of the 
neighboring fibrin molecules. It was shown that the 
sequences Gly-Pro-Arg and Gly-His-Arg which are ex- 
posed on a and p chains after removal of the FPA and 
FPB, respectively, play an important role in the forma- 
tion of the central polymerization sites. Synthetic pep- 
tides Gly-Pro-Arg-Pro and Gly-His-Arg-Pro were 
shown to bind to fibrinogen [2]. They also bind to the 
D,-fragment [3] which derives from the terminal region 
of fibrinogen and contains intact C-terminal regions of 
both p and y chains. The D,-fragment binds Gly-His- 
Arg-Pro but does not bind Gly-Pro-Arg-Pro, indicating 
that the 13 kDa C-terminal region of the y-chain, miss- 
ing in the D,-fragment, is involved in the formation of 
a polymerization site complementary to the latter se- 
quence [4]. A number of attempts have been made to 
Correspondence andpresent address. L.V. Medved. J. Holland Labo- 
ratory, American Red Cross, 15601 Crabbs Branch Way, Rockvdle, 
MD 20855, USA. Fax: (1) (301) 738 0794. 
Published by Elsevier Science Publrshers B V 239 
further localize this site on the fibrinogen molecule 
[5-101. 
Less is known about the other polymerization site 
complementary to the Gly-His-Arg sequence. Based on 
the high homology between fibrinogen p and y chains 
it was hypothesized that this binding site should be 
situated in the C-terminal part of the P-chain, [l l] al- 
though no direct experimental evidence exists. To test 
this hypothesis and to further localize this site we have 
prepared a Gly-His-Arg-Pro peptide labeled with the 
fluorescent Dansyl group and analyzed its binding to 
different fragments derived from the C-terminal part of 
fibrinogen. 
2. MATERIALS AND METHODS 
2.1. Preparation of proteins and fragments 
Bovine fibrinogen (clottability 98%) was prepared from oxalate 
bovine plasma by salting out with so&urn sulphate [12]. The D,(95 
kDa) fragment was obtamed from a 2-h plasmin digest of fibrinogen 
and purified by the method described m ref. [13]. The D,(82 kDa) 
fragment was obtained from an early pepsin digest of the D, fragment 
as described earher [13]. The D,(63 kDa) fragment was prepared by 
chymotrypsm digestion of the D, fragment as described in ref. [14]. 
The TSD(28 kDa) fragment was prepared from prolonged pepsin 
digest of the D, fragment as was reported earher [15]. The fibrm 
monomer was prepared by dissolving the non-crosslinked fibrin clot 
at 4°C with 0.02M acetic acid as described m ref. [16]. 
2.2. Peptlde synthesis 
Gly-His-Arg-Pro peptide (GHRP) was synthesized by condensation 
of benzyl-oxycarbonyl-glycyl-histidine and N-(arginyl-prolyl)-N’-tert- 
butyloxycarbonyl-he xamethylene &amide in the presence of dlphen- 
ylphosphorylazide. The tert-butyloxycarbonyl group was removed by 
treating the peptide with acetIc acid saturated with HCl. A Dansyl 
group was introduced at the C-terminus of the peptide by reaction 
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with Dansylchloride. The final product was deblocked by catalytic 
hydrogenolysis and purified by chromatography on silicagel. The pep- 
tide obtained (GHRP-Dansyl) was homogeneous accordmg to thin- 
layer chromatography and HPLC. 
The polymerization process was inittated by lo-fold dtlution of the 
concentrated fibrin monomer solution (2.5 mg/ml) with 0 02 M ver- 
onal buffer, pH 7.4, containing 0.13 M NaCI, 1 mM CaCl,, 2 mM 
&-aminocaproic acid and different amounts of the D, fragment. The 
appearance of the fibrin clot was registered visually. The inhibitory 
effect of the D, fragment was expressed by the value (t-t,i/t,, where 
I, and I represent clottmg times without and with inhibitor. respec- 
tively [l7]. In the experiments where the ehminatmg effect of the 
GHRP-Dansyl peptide on anticlotting activity of the D, fragment was 
studied the same amount of the D, (0 4 mg/mI) was incubated with 
various concentrations of the peptide and the inhibitory effect of the 
mixture was tested. 
The equihbrium dialysis was performed m test tubes usmg Spectra/ 
Por molecularporous membrane tubing (6.4 mm diameter). Each frag- 
ment was dissolved in I ml of 0.05 M Tris. pH 7.4. 0 I M NaCI, I mM 
CaCI, and 0.02% NaN, buffer (TBS) to a final concentration of IxIO-~ 
M and dialyzed at room temperature while stirring against 20 ml of 
the same buffer contaming various concentrations of GHRP-Dansyl 
pepttde. After 48 h the fluorescence spectra of the fragment solution 
and dialysis buffer were recorded on Hitachi 650-IOS spectrofluortme- 
ter in the spectral range between 460 and 620 nm with excitation at 
/1=335 nm. The concentration of fragments m solution has determmed 
spectrophotometrically using the following values off& for I % solu- 
tion: 20.0 for the D, and D, fragments [13], 16.0 for the D, fragment 
[I41 and 8.0 for the TSD fragment [l5]. 
3. RESULTS AND DISCUSSION 
In order to monitor the binding of the synthetic 
tetrapeptide GHRP to different fibrinogen fragments it 
was labeled with the fluorescent Dansyl group. The lat- 
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Fig. I. Infuence of the GHRP-Dansyl peptide on the anticlotting 
effect of the D, fragment. Panel A represents the inhibition of the 
polymerization of fibrm by Increasing amounts (up to 0.4 mg/ml) of 
the D,, fragment Panel B demonstrates progressive ehmination of the 
anticlotting effect of D, fragment (0.4 mg/mI) when first incubated 
with various amount of the GHRP-Dansyl peptide. the X axis repre- 
sent5 molar ratio. 
460 
I I I I I I , 
500 540 560 620 
Wavelength (nm) 
Fig. 2 Bmdmg of the GHRP-Dansyl peptide to different fibrmogen 
fragments. Fluorescence spectra of the E (dotted hne) and D,, D,, D, 
and TSD fragment soluttons (sohd lines I through 4) were recorded 
after dialysis agamst TBS containing 2x0-’ M GHRP-Dansyl peptide 
whose fluorescence spectrum IS presented by the dashed line. The 
fragment concentration was 1x10-’ M. 
ter has a fluorescence spectrum which does not overlap 
with that of the protein and allows quantitation of the 
bound peptide by fluorescence. It was shown that the 
binding and/or inhibition activities of the synthetic pep- 
tides GPR or GHR are very sensitive to simple struc- 
tural alteration [3]. For example, acetylation of the 
amino group of the Gly residue in both tetrapeptides 
leads to elimination of their binding properties. To pre- 
serve the activity of the Gly-His-Arg-Pro peptide the 
Dansyl was coupled to its C-terminal proline residue as 
described above. 
Although synthetic peptide GHRP does not inhibit 
the fibrin polymerization process it binds to fibrinogen 
and/or fragment D [Z&4] and reduces their anticlotting 
effect by blocking the polymerization sites [18]. To 
check the activity of the Dansyl-labeled tetrapeptide we 
investigated the influence of the latter on the anticlot- 
ting activity of the Dn fragment. The results are pre- 
sented in Fig. 1. The addition of increasing amounts of 
the D, fragment to the monomeric fibrin caused pro- 
gressive retardation of the clotting time (Fig. 1 A). When 
the D,, fragment was first incubated with increasing 
amounts of the GHRP-Dansyl the clotting time was 
substantially reduced indicating inactivation of the D, 
fragment by the peptide (Fig. 1B). The degree of the 
inactivation was approximately the same as for unla- 
beled GHRP peptide tested earlier [IS]. These results 
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indicate that the labeled peptide is an effective inhibitor 
of the anticlotting activity of the D, fragment, i.e. func- 
tional activity of the Gly-His-Arg-Pro sequence was not 
affected substantially by the attachment of the Dansyl 
group to its C-terminal proline residue. 
The fluorescence spectrum of a solution of 1x10-” M 
GHRP-Dansyl peptide is presented in Fig. 2 (dashed 
line). Fragment E, which presumably does not bind 
GHRP [2] and was selected as a control, did not exhibit 
any fluorescence in this spectral region. After dialysis 
against the peptide solution, the E fragment solution 
acquired fluorescence whose intensity coincided with 
that of free peptide due to reaching an equilibrium (dot- 
ted line). At the same time, the fluorescence intensity of 
the D, fragment dialyzed against the peptide solution 
was substantially higher (Fig. 2, solid line 1) due to 
binding of the peptide to the D, fragment. Additional 
experiments performed with the D, fragment dialyzed 
against different concentrations of the tetrapeptide al- 
lowed us to obtain a saturation curve and calculate the 
binding constant (k,) and number of binding sites (n). 
The value of the k, and n obtained from four repeat 
experiments was found to be 3.4 & 0.5 x103 M-’ and 
0.92 f 0.1, respectively (Fig. 3). These values are close 
to those reported earlier for human fibrinogen and D, 
fragment [3,4]. After dialysis the intensity of the fluores- 
cence of the D, and DY fragment solutions was higher 
than that of the GHRP-Dansyl alone while the intensity 
of the TSD fragment was the same as that of the 
tetrapeptide. This indicates that the GHRP-Dansyl 
binds to the D, and D, fragments and does not bind to 
the TSD fragment. 
We have previously shown that the DH (95 kDa) frag- 
ment consists of five domains. Among them are coiled- 
coil thermostable TSD domains formed by the N-termi- 
nal regions of all three OZ. p and y chains and two pairs 
GHRP-Dansyl 
fi -domain fit-domain 
A 
a 
Y 
I I I 
I I I 
I ; I 
\ .________ J ‘_______ ’ 
y -domain 7 C-domain 
Fig. 4. Diagram of the arrangement of TSD, p. /K and y, yC domams 
in the D, fragment and binding of GHRP-Dansyl to them. Dashed 
lines indicate y and yC domains which are removed upon preparation 
of the D, fragment. Individual polypeptide chains are denoted as a. 
p and y. 
of thermolabile domains, /?, PC and y, yC, formed by 
the C-terminal regions of the /I and y chains, respec- 
tively [ 14,191. The domain structure of the D, fragment 
is presented in Fig. 4. These domains could be prote- 
olytically removed in a step-wise manner to produce 
DJ82 kDa). D,(63 kDa) and TSD(28 kDa) fragments 
[ 141. The latter is represented by the TSD domain, while 
the two former contain in addition to the TSD also p 
+ PC + y and /? + j?C domains, respectively. The exact 
amino acid sequence of the fragments will be published 
elsewhere (Litvinovich et al., in preparation). D, is the 
smallest fragment which still binds Dansyl labeled 
tetrapeptide (Fig. 2). Because it differs from the TSD 
fragment by the presence of the j? and PC domains, the 
latter two contain the polymerization site complemen- 
tary to the central Gly-His-Arg containing counterpart. 
The /I and PC domains are formed by the C-terminal 
part of the p chain [14,19]. Thus this region of the 
fibrinogen molecule is involved in the formation of the 
polymerization site complementary to the Gly-His-Arg 
containing counterparts as was predicted by Doolittle 
and Laudano [l 11. 
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Fig. 3. Scatchard analysts of binding of the GHRP-Dansyl pepttde to 
the fibrmogen fragment D,. Open and closed squares represent results 
obtained from two different expertments. B. concentratton of the pep- 
ttde bound to D, fragment; F, concentration of free peptide. 
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